CD8A and neoplasm: The T cell–inflamed tumour microenvironment has become a biomarker for checkpoint blockade immunotherapy response.34 As the RRCR group had a significantly higher infiltration of CD8 T cells, we wondered whether this group of patients would be more suited for checkpoint blockade immunotherapy than other groups.